Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

HYDERABAD, India (Reuters) - India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major drugmaker Biocon Ltd said ahead of Prime Minister ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and ...

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Biocon Ltd is quoting at Rs 397.1, up 1.76% on the day as on 12:49 IST on the NSE. The stock is up 36.81% in last one year as compared to a 7.61% gain in NIFTY and a 18.78% gain in the Nifty Pharma ...

Shares of Biocon Ltd closed slightly higher at ₹357.15 on the BSE today, up 0.44% or ₹1.55, ahead of the earnings ...

Biocon Ltd.'s disappointing Q3FY25 performance was largely due to exceptional items, with adjusted net profit standing at Rs 13 crore, and revenue growth of 7% on a like-for-like basis.

Biocon Ltd share price was up by 1.72% from the previous closing price of ₹390.25. Who are peers of Biocon Ltd? The peers of Biocon Ltd are Sun Pharmaceuticals Industries Ltd, Divis Laboratories ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...